Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21743155 | 0.89 | CHRM3 (0.38) | CYP3A4CYP1A2CYP2D6DRD2DRD3 | |
| SCHEMBL21667895 | 0.89 | CHRM3 (0.38) | CYP3A4CYP1A2CYP2D6DRD2DRD3 | |
| SCHEMBL17212848 | 0.89 | CHRM3 (0.38) | CYP3A4CYP1A2CYP2D6DRD2DRD3 | |
| SCHEMBL23588529 | 0.87 | DRD2 (0.42) | DRD2DRD3KDM2B | |
| SCHEMBL19124611 | 0.85 | HTR2A (0.37) | CYP3A4HTR2ACYP1A2CYP2D6DRD2 | |
| SCHEMBL772852 | 0.85 | BCHE (0.33) | BCHEACHEMAOBNPSR1 | |
| SCHEMBL7702796 | 0.82 | NPSR1 (0.40) | CYP3A4HTR2ACYP1A2CYP2D6DRD2 | |
| SCHEMBL21667902 | 0.81 | — | — | |
| SCHEMBL23023339 | 0.80 | CHRNB2 (0.39) | HTR2ACYP2D6DRD3KCNH2MAOB | |
| SCHEMBL2621581 | 0.80 | CHRNB2 (0.39) | HTR2ACYP2D6DRD3KCNH2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | NLN, GRIN2C, BCHE | CYP3A4 1348/4885HTR2A 334/4885CYP1A2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.